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Study rationale 
The development of targeted therapies in recent years 
has led to increasing numbers of specialised anti-
cancer treatments. In the United Kingdom (UK), the 
National Institute for Health and Clinical Excellence 
(NICE) has issued guidance on the use of such 
treatments to the NHS. This occurs through NICE’s 
Single Technology Appraisal (STA) programme, 
which aims to assess their effectiveness early to 
allow release of guidance around the issuing of 
marketing authorisation.  
Large clinical trials are the standard for making 
treatment decisions, and non-publication of the 
results can lead to bias in the literature, contributing  
to inappropriate medical decisions.1 Increasingly 
oncology trials are stopping early,2 with more than a 
doubling rate across therapeutic areas since 1990.3 
This is reflected in over 78% of randomised 
controlled trials (RCTs) in the last three years using 
an interim analysis for registration purposes. 2 NICE 
has already issued guidance in the absence of full 
peer-reviewed trial data being available.4 It is 
therefore important to establish the pattern of full 
publications to inform the developing methodology 
for systematic reviews in this fast moving area (for 




• The key objective was to identify the delay between 
conference abstracts and full publication of results 
from RCTs of new anti-cancer agents for breast 
cancer.  
• A secondary objective was to identify whether there 
are any apparent biases in the publication and 
reporting of these trials.  
Methods (cont.) 
• Inclusion criteria, decisions on quality criteria and data 
extraction were applied independently by two 
reviewers, with any differences in opinion resolved 
through discussion.  
• Data were extracted from the included studies using a 
pre-designed and piloted data extraction template to 
report information on the month and year of publication 
of each included study, the numbers of participants in 
each study arm (to allow identification of linked 
studies), and key outcome data from each study.  
• Full publications and abstracts were linked by 
reference to trial identifiers, trial arms, numbers of 
participants and any other available information.  
• No statistical analysis was performed due to the small 
sample size.  
• Mean time between publication of abstracts and full 
paper: for trials reporting key outcomes in abstract form 
but without a full publication of these results, a 
calculation of the mean time between publication of the 
abstract and the end of the search dates was made. 
Calculation of time to publication was restricted to 
abstracts and corresponding full papers which reported 
measures of overall survival or aspects of disease 
progression. Abstracts which only reported baseline 
characteristics, adverse events or quality of life scores 
were not included in the analysis. 
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• Around 40% of abstracts presented at scientific 
meetings are never published in full.6 
• Breast cancer trials have been reported as 
having the highest proportion of unpublished 
studies, at 36% at 5 years after publication of the 
abstract, compared to 26% for all cancer.7  
• Publication delay or failure to publish current 
research can lead to a biased pool of evidence.7 
• Many new drugs will have only recently gained 
regulatory approval and the complete body of 
evidence may not be available for public 
scrutiny.8  
• Rapid and full publication of trial results is not 
only vital for the effective appraisal of the efficacy 
of new technologies upon which treatment 
decisions are made, but also of interest to all of 
those concerned with new therapies, particularly 
in the fight against cancer.  
• Future research should investigate the effect of 
publication delays on decision making, as well as 
on the availability of new drug treatments in 
clinical practice for these and other anti-cancer 
drugs.  
Methods 
• A systematic review was conducted.  
• A full search of existing NICE STA appraisals of 
anti-cancer drugs for breast cancer was undertaken 
by one reviewer and checked by a second.   This 
included technologies which were currently in the 
process of being appraised or due to be by NICE.  
• We identified 11 areas of NICE guidance for eight 
anti-cancer drugs.  
• As many of the interventions had previous 
technology assessments for NICE, literature 
searches were limited to studies published after the 
cut-off dates of searching in the previous 
publications until August 2007,  
• A number of electronic databases were searched, 
including: Ovid MEDLINE®; EMBASE; DARE, the 
Cochrane library and ISI Proceedings.  
• The National Research Register and 
ClinicalTrials.gov were searched to identify RCTs in 
progress.  
• Websites of international conferences were also 
searched, from 5 years prior to the date of 
marketing authorisation until the present date. 
 
Inclusion criteria: 
• Population: Adults (age >18) with breast cancer 
(meeting specific disease stage criteria as 
appropriate) 
• Comparator: Any, including placebo 
• Outcomes: time to full publication, overall 
survival and any measures relating to time to 
disease progression 
• Study type: Systematic Reviews and RCTs  
 
• 6 interventions met the criteria (see Table 1).  
• RCTs were quality assessed using recognised 
criteria (Centre for Reviews and Dissemination, 
2001).  
 
This report was commissioned by the NIHR HTA Programme 
Identified on searching (after duplicates 
 removed) n = 1556 
Titles and abstracts inspected using 
 protocol screening criteria* 
Excluded:  
n = 1486 
Papers inspected n=71  Excluded:  
n = 30 
Included references n = 41 
Of which n =18 RCTs  
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Table 1: Interventions and NICE indications 
Results  
• A total of 1556 publications were identified through 
literature searching.  Of these, 1365 were excluded on 
title and abstract.  The protocol amendment led to the 
exclusion of a further 121 studies. 
• 71 studies were requested for more in-depth screening, 
leading to the exclusion of another 30 studies. 
• The remaining 41 publications consisted of 18 RCTs, 
including at least one arm of treatment and meeting the 
indications noted in Table 1 (for reference list see 
Takeda et al, in press5). The 18 RCTs (see Takeda et 
al, in press) consisted of 2 RCTs each for paclitaxel and 
gemcitabine, 3 RCTs each for docetaxel, trastuzumab 
and lapatinib, and 5 RCTs for bevacizumab.  
Breast cancer drug   Indications considered by NICE 
Early breast cancer  
Docetaxel  In combination with doxorubicin and 
cyclophosphomide for women diagnosed 
with operable node-positive breast cancer  
Paclitaxel  As monotherapy for node-positive breast 
cancer  
Trastuzumab  Monotherapy as second-line treatment  
Advanced/metastatic cancer  
Gemcitabine  In combination with paclitaxel  
Lapatinib  In combination with capecitabine  
Bevacizumab  In combination with capecitabine, 
docetaxel, paclitaxel or cylophosphomide 
and methotrexate 
†Lapatinib and bevacizumab were ‘appraisals in progress’at the time of our 
study. Indications considered here reflect those identified in the literature for 
bevacizumab and the combination in NICE’s scope for lapatinib. 
Figure 1. Flow chart of systematic review process  
*Protocol amendment, limiting searches to NICE STA drugs 
Results (cont.) 
• The mean time delay between publication of 
abstracts to full publication of the RCTs was 9 
months (range 5 - 19 months). 
• 11 trials were without a full publication of data 
presented in an abstract or conference proceeding, 
with the duration between publication of the 
abstracts and the end of our searches (August 
2007) varying from 3 - 38 months.  
• Mean time awaiting publication (to August 2007) 
was 16.5 months. 
• 7 trials were without full publications at least 12   
months after the abstract data was presented and 
4 remain unpublished after 21 months or more. 
Limitations 
• This review was limited to drug combinations and 
patient groups appraised under the NICE STA 
programme and resulted in a sample size too small 
for a statistical analysis. Only most relevant 
outcomes to the NICE process were data 
extracted.  
• Strengths of this review are that the authors have 
no vested interest in these interventions, and that 
the principles of good practice in systematic 
reviewing have been followed.  